Thank you for submitting your manuscript for consideration by The EMBO Journal. Two referees have now evaluated it, and their comments are shown below. As you will see, while both referees consider the study as very interesting and referee 1 is more positive, referee 2 feels strongly that the role of WAC on Golgi dynamics would need to be addressed in considerably more depth before he/she can support publication of the study here. In fact, the concern itself has also been raised by referee 1. On balance, we should thus be able to consider a revised manuscript, in which the referees' concerns are addressed in an adequate manner and to their satisfaction. However, it will be important to develop the study further along the lines put forward by referee 2. Please do not hesitate to get back to me in case you would like to discuss any aspect of the revision further.
I should add that it is EMBO Journal policy to allow only a single round of revision, and acceptance or rejection of your manuscript will therefore depend on the completeness of your responses in this revised version as well as on the final assessment by the referees.
When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Peer Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html
We generally allow three months as standard revision time. As a matter of policy, competing manuscripts published during this period will not negatively impact on our assessment of the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely, Editor
The EMBO Journal
Referee #1 (Remarks to the Author):
This article re-visits the function of the different p97 complexes in membrane fusion at the Golgi and in the ER and links it to the deubiquitination activity of VCIP135, a protein also known to be involved in fusion events at these organelles.
On one hand, p97/p47 has been shown to be required for Golgi membrane fusion at the end of mitosis that require the deubiquitination activity of VCIP135. On the other hand, p97/p37 is involved in membrane fusion in interphase which does not require the deubiquitination activity of VCIP135, but still requires the presence of this protein.
Here, the authors identify a novel VCIP135 interacting protein WAC that localizes to the Golgi (and the nucleus). WAC promotes/enhances the deubiquination activity of VCIP135 (that is further enhance through binding to p97), both in vitro and using a cell free reassembly assay, in the context of the p97/p47 but not p97/p37.
The article is very interesting as it places, once more, ubiquitination/deubiquitination at the centre of regulation of complex formation and modulation of cellular activity. This is also biochemistry at its best, combining rigorous approaches and clever mutagenesis strategies with microscopy approaches in vivo and functional cell free assays.
I find the paper experimentally very convincing , also very clearly written with a clear message and a strong attempt at reconciling data from others. WAC is clearly a new partner to the molecular machine driving fusion at the Golgi at the end of mitosis and in the ER.
Minor points -The authors should be carefully at claiming that WAC is involved in the biogenesis of the Golgi (in their EM Golgi analysis of the WAC depleted cells). It could also be maintenance. And it would be interesting to know whether transport is inhibited in these fragmented Golgi.
-Second, the authors should mention that the IF detects the endogenous WAC using the antibody they raised.
-It would be good to have some quantitation of the stimulation of the binding between VCIP135 and WAC by p97.
Referee #2 (Remarks to the Author):
In this manuscript, Kondo and colleagues report on a new protein component of the p97/p47/VCIP135 complex (which they call WAC) that is involved in the fusion of Golgi membranes during Golgi reassembly after mitotic fragmentation. They show that WAC interacts directly with VCIP135, and they also analyse the mechanism of action of WAC (it stimulates the VCIP135 de-ubiquitinating activity that is required for Golgi membrane fusion).
In addition, in a separate section of the manuscript, they have analysed the role of the components of the same complex in homotypic fusion of fragmented ER membranes.
My comments/ concerns are as follows:
1) The data on the in-vivo action of WAC are confusing. The authors report that the depletion of WAC induces Golgi vesiculation. However, they also state that WAC is involved only in the p97/p47 fusion pathway that operates on mitotically fragmented Golgi membranes, and not in the p97/p37 pathways for fusion of interphase Golgi membranes. Why is there Golgi vesiculation in WAC-depleted cells? Does this reflect a failure in the reassembling of the Golgi after mitosis? However, we do not know if there has been any mitosis during the siRNA treatment that was used to deplete WAC. Also, if this were the case (ie, if the Golgi vesiculation were due to failed postmitotic Golgi reassembly), we should expect not just partial, but dramatic, vesiculation. There is a disturbing lack of internal consistency here that should be taken care of.
2) The authors perform an in-vitro postmitotic Golgi reassembly assay and show that p97/p47-mediated Golgi reassembly is blocked by antibodies against WAC. They also show that Golgi reassembly is inhibited when, instead of the wild-type protein, the assay includes theVCIP135 mutant that cannot bind WAC. This is a key experiment and the data are fine; however, exactly because this is a key experiment, one would like to see these results confirmed by convergent approaches. For instance, the VCIP135 mutant should inhibit Golgi reassembly by competing with the endogenous protein for WAC binding; or the assay could be carried out using membranes prepared from WAC-depleted cells. These seem to be simple experiments that would strengthen the conclusion, but they have not been carried out; I think they should be.
3) Another important question is whether WAC is also required for in-vivo postmitotic Golgi reassembly. The experiment seems feasible (deplete WAC, and examine Golgi reassembly after mitosis), but apparently this has not been done; it definitely should be.
4) The following is a minor point. Considering the stoichiometry of the in-vitro reaction, the deubiquitinating (DUB) activity is vanishingly small. It is difficult to understand how this might contribute to membrane fusion (though this has been previously published by others). In this study the authors shows that WAC increases the DUB activity in an assay with purified proteins. These results are clear; however, the authors also attempt to show that WAC has the same effect in Golgi membranes using a VCIP135 mutant that does not bind WAC. These results provide only indirect evidence for the dependence of the DUB reaction on WAC when Golgi membranes are used as substrate. This should be pointed out.
5) The second part of the manuscript is devoted to an analysis of ER reassembly after fragmentation and to the roles in this reassembly of the various components that have been analysed in the Golgi assay. A clear link with the Golgi part is missing. The authors have analysed the roles of certain components in Golgi reassembly, and they now want to see whether the same components also function for the ER. This is not specifically necessary, although it does not hurt to include it, if it can be presented properly. If they want to keep this part in then they should at least clarify the logical flow. The best way is probably to start form the question of whether WAC is also needed for ER reassembly.
6) Overall, the in-vitro ER reassembly experiments are convincing and have been carried out proficiently, as far as I can judge, although the logical flow is confusing. They go from in-vitro to in-vivo experiments, and then back to in-vitro data. The first four lines of page 10 have something wrong with them, as they are not understandable (is the cytosol depleted of p97? I cannot figure this out). Also, in-vivo data on the in-vivo role of the p97 fusion machinery components are almost completely missing.
Overall, I would say that this study identifies a new component in the p97 Golgi fusion machinery, and that this is valuable. However, many parts of the manuscript are seriously flawed, and there is a lot of work that is needed to bring these parts up to a level suitable for publication in the EMBO J. Response to Reviewer #1
1. The 1st comment in minor points: The authors should be carefully at claiming that WAC is involved in the biogenesis of the Golgi (in their EM Golgi analysis of the WAC depleted cells). It could also be maintenance.
Ans: Following your comment and the request by Reviewer#2, we investigated Golgi reassembly at the end of mitosis in WAC-depleted cells. The results are presented in new Supplemental Figure S3 . Golgi was reassembled at cytokinesis in mock-treated cells (panels c-e). In contrast, in WAC-depleted cells, Golgi reassembly was partially inhibited even at cytokinesis (panels m-o). These in vivo results suggest the requirement of WAC in Golgi reassembly at the end of mitosis. An in vitro Golgi reformation assay showed that WAC was required only for the p97/p47 pathway (Fig. 6A) , which is reported to be specialized for the reassembly of organelles at the end of mitosis (Uchiyama et al., J Cell Biol, 161: 1067 -79, 2003 . Taking all of these facts into consideration, we have suggested that WAC is required for the biogenesis of the Golgi. We added one new paragraph in Results (p9, the 2nd paragraph).
2. The 1st comment in minor points: … And it would be interesting to know whether transport is inhibited in these fragmented Golgi.
Ans: Following this suggestion, we performed the transport assays of VSVG-ts045 in WACdepleted and mock cells. The results are shown in Figure R1 for Reviewers. We could not observe any differences in the transport of VSVG-ts045 from the ER to the plasma membrane between WAC-depleted and mock cells.
3. The 2nd comment in minor points: Second, the authors should mention that the IF detects the endogenous WAC using the antibody they raised.
Ans: Following your comment, we amended the text (p5, the 2nd paragraph).
4. The 3rd comment in minor points: It would be good to have some quantitation of the stimulation of the binding between VCIP135 and WAC by p97.
Ans: Following your suggestion, we added new Supplemental Figure S2 .
Response to Reviewer #2
1. Comment: 1) The data on the in-vivo action of WAC are confusing. The authors report that the depletion of WAC induces Golgi vesiculation. However, they also state that WAC is involved only in the p97/p47 fusion pathway that operates on mitotically fragmented Golgi membranes, and not in the p97/p37 pathways for fusion of interphase Golgi membranes. Why is there Golgi vesiculation in WAC-depleted cells? Does this reflect a failure in the reassembling of the Golgi after mitosis? However, we do not know if there has been any mitosis during the siRNA treatment that was used to deplete WAC. Comment: 3) Another important question is whether WAC is also required for in-vivo postmitotic Golgi reassembly. The experiment seems feasible (deplete WAC, and examine Golgi reassembly after mitosis), but apparently this has not been done; it definitely should be.
Ans: Since the above comment and request are tightly related, we want to respond to them together. Following your request and the comment by Reviewer#1, we investigated Golgi reassembly at the end of mitosis in WAC-depleted cells. The results are presented in new Supplemental Figure S3 . Golgi was reassembled at cytokinesis in mock-treated cells (panels c-e). In contrast, in WAC-depleted cells, Golgi reassembly was partially inhibited even at cytokinesis (panels m-o). These in vivo results suggest the requirement of WAC in Golgi reassembly at the end of mitosis. An in vitro Golgi reformation assay showed that WAC was required only for the p97/p47 pathway (Fig. 6A) , which is reported to be specialized for the reassembly of organelles at the end of mitosis (Uchiyama et al., J Cell Biol, 161: 1067 -79, 2003 . Taking all of these facts into consideration, we have suggested that WAC is required for Golgi reassembly at the end of mitosis.
We added one new paragraph in Results (p9, the 2nd paragraph).
2. Comment: 1) …Also, if this were the case (ie, if the Golgi vesiculation were due to failed postmitotic Golgi reassembly), we should expect not just partial, but dramatic, vesiculation.
There is a disturbing lack of internal consistency here that should be taken care of.
Ans: The NSF pathway is also reported to function in Golgi reassembly at the end of mitosis (Rabouille et al., Cell, 82, 905-14, 1995; Rabouille et al., Cell, 92, 603-610, 1998) . We also reported that the p97/p37 pathway functions in Golgi reassembly at the end of mitosis as well as its maintenance during the interphase (Uchiyama et al., Dev Cell, 11, . Considering that the NSF and p97/p37 pathways still functioned in Golgi reassembly in WAC-depleted cells, it is reasonable that the depletion of WAC caused partial, but not dramatic, vesiculation in the Golgi.
To avoid confusion, we amended the text in Introduction (p3, the 2nd paragraph).
3. Comment: 2) For instance, the VCIP135 mutant should inhibit Golgi reassembly by competing with the endogenous protein for WAC binding; or the assay could be carried out using membranes prepared from WAC-depleted cells. These seem to be simple experiments that would strengthen the conclusion, but they have not been carried out; I think they should be.
Ans: We appreciate your kind suggestion. Although we agree that the two experiments you suggested would strengthen the conclusion, we have several technical problems to perform them. At first, we would like to explain a technical problem in your first experimental plan: the VCIP135 mutant should inhibit in vitro Golgi reassembly by competing with the endogenous protein for WAC binding. For the competition experiment, we need to add an excess amount of VCIP135. However, as presented in Figure R2 for Reviewers, the dose-curve of VCIP135 is biphasic in an in vitro Golgi reformation assay and the addition of an excess amount of VCIP135wt inhibited p97/p47-mediated Golgi reassembly. This is the reason we used saltwashed membranes, not salt-unwashed membranes, in Figure 6B . When exogenous VCIP135 was added to salt-unwashed Golgi membranes, which still contained endogenous VCIP135, an inhibitory effect was observed in an in vitro Golgi reformation assay. It is hence difficult to carry out the competition experiment using VCIP135wt/mutant.
We next want to explain a technical problem in your second experimental plan: an in vitro Golgi reassembly assay using membranes prepared from WAC-depleted cells. At this moment, we can obtain highly purified Golgi membranes only from liver tissues (Hui et al, 'Purification of Rat Liver Golgi Stacks', Cell Biology: A Laboratory Handbook, 1998). Moreover, it would be much more difficult to prepare highly purified Golgi membranes from WAC-depleted cells whose Golgi membranes are vesiculated.
Your suggested ideas seem to be very fascinating, we feel. Nevertheless, it is difficult to perform these experiments due to the technical problems mentioned above.
Comment: 4)
The following is a minor point. Considering the stoichiometry of the in-vitro reaction, the de-ubiquitinating (DUB) activity is vanishingly small. It is difficult to understand how this might contribute to membrane fusion (though this has been previously published by others). In this study the authors shows that WAC increases the DUB activity in an assay with purified proteins. These results are clear; however, the authors also attempt to show that WAC has the same effect in Golgi membranes using a VCIP135 mutant that does not bind WAC. These results provide only indirect evidence for the dependence of the DUB reaction on WAC when Golgi membranes are used as substrate. This should be pointed out.
Ans: We perfectly agree your comment and amended the text (p7, the last paragraph) following your comment.
Comment: 5)
The second part of the manuscript is devoted to an analysis of ER reassembly after fragmentation and to the roles in this reassembly of the various components that have been analysed in the Golgi assay. A clear link with the Golgi part is missing. The authors have analysed the roles of certain components in Golgi reassembly, and they now want to see whether the same components also function for the ER. This is not specifically necessary, although it does not hurt to include it, if it can be presented properly. If they want to keep this part in then they should at least clarify the logical flow. The best way is probably to start form the question of whether WAC is also needed for ER reassembly.
Ans: We changed the final section of Results (p9-11) to clarify the logical flow: we started from the question of whether WAC is also needed for ER reassembly, following your suggestion.
6. Comment 6): Overall, the in-vitro ER reassembly experiments are convincing and have been carried out proficiently, as far as I can judge, although the logical flow is confusing. They go from in-vitro to in-vivo experiments, and then back to in-vitro data.
Ans: Following your advice, we changed Figure 9 . Ans: Endogenous VCIP135, p47 and p37 were removed from the membranes by salt-wash and from the cytosol by the depletion with p97-beads (Hetzer et al., Nat Cell Biol, 3, p1086-91, 2001 , and recombinant VCIP135, p47 and p37 were added instead.
To avoid confusion, we amended the text (p10, the 2nd paragraph).
8. Comment 6): Also, in-vivo data on the in-vivo role of the p97 fusion machinery components are almost completely missing.
Ans: We previously published the in vivo data on the in vivo role of the other components of the p97 fusion machinery as follows. The in vivo function of p47; J Cell Biol, 159, p855-866, 2002 The in vivo function of p37; Dev Cell, 11, p803-816, 2006 The in vivo function of VCIP135; J Cell Biol, 159, p855-866, 2002 We mentioned these previous findings in Discussion (p15, L2-3). Additionally, we have inserted one new sentence in Results (p10, the 1st paragraph) to avoid confusion. Thank you for sending us your revised manuscript. Our original referees have now seen it again, and you will be pleased to learn that in their view you have addressed their criticisms in a satisfactory manner, and that the paper will therefore be publishable in The EMBO Journal.
Still, there are two editorial issues that need further attention. First, please add the statistical details including the number of independent repeats to the legends of figures 4B and S2, and information on the scale bars to the legends of figures 8A and 8C.
Second, prior to accepting manuscripts we always do a cross check to see if there is any similarity between the accepted manuscript text and previous published work. In your case, the cross check picked up some passages that show similarity to a number of your previous papers (please see attachment). I recognise that it is your own work that the present manuscript text shows similarity to and that for some of the passages it may not be straightforward to use alternative phrases. Still, I would like to ask you to modify the highlighted passages.
Please let us have an amended version of the manuscript as soon as possible. I will then formally accept the manuscript.
Thank you very much again for considering our journal for publication of your work.
Yours sincerely,
Editor
------------------------------------------------REFEREE COMMENTS
The authors have satisfactorily addressed the points I had raised and since I was already supportive of publication after the first round, I am now entirely convinced that this article should be published in the EMBO J.
The authors have thoroughly addressed my concerns wirh new experiments and textual changes, as required.
The revised manuscript is sufficiently novel and complete to be considered for publication. 5. In order to decrease similarity to our previous papers, we have amended the text where appropriate.
I hope that the revised manuscript is formally acceptable for publication in EMBO J.
